Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

High-Risk neuroblastoma (HR-NB) is an aggressive pediatric cancer, with only half of patients surviving. New Approaches to Neuroblastoma Therapy (NANT) headquartered at Children's Hospital Los Angeles is the only group focused on new treatments based on lab data for HR-NB. NANT includes a team of 18 children's hospitals across nationally and internationally working together to design new treatments, treat patients, and use what is learned to design the next treatments. New treatments include helping patients’ own immune system kill tumor by increasing and activating immune cells. Another treatment uses radiation therapy focused on the tumor combined with medicines to help the immune system recognize tumor. Trials include special tests on patients' blood and bone marrow to understand how treatments work, find tiny amounts of tumor and new therapy targets. NANT trials help kids with aggressive NB that has come back. Funds administered by Children's Hospital Los Angeles.

This grant is named for the LukeStrong a Force Against Neuroblastoma Childhood Cancer Fund. When Luke was 5 years old, he was diagnosed with high-risk neuroblastoma. He is now in his teens and still in active treatment for relapsed neuroblastoma. Since 2014 Luke’s “Never tell me the odds” attitude has inspired his family and friends to shave their heads, fundraise with St. Baldrick’s, and help conquer childhood cancers.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Malignant Germ Cell Tumors International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Malignant Germ Cell Tumors International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Malignant Germ Cell Tumors International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Malignant Germ Cell Tumors International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Malignant Germ Cell Tumors International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

Although germ cell tumors are the most common solid tumors of adolescents and young adults, care and progress has been hampered by fragmentation between pediatric and medical oncology. No major breakthrough in therapy has occurred for over 4 decades, and limited molecular understanding hampers the ability to tailor therapy or discover new drugs that could change outcomes. Through collaboration and joint projects and initiatives, the Malignant Germ Cell Tumors International Consortium (MaGIC) of the world’s leading scientists and clinicians from both pediatric and medical oncology has been able to make some important advances in clinical trial design and biologic understanding of this cancer: a new molecular test to detect relapse, a new molecular test to assign risk group and several jointly designed adolescent and young adult clinical trials using novel drugs and treatment approaches. Funds administered by Dana–Farber Cancer Institute.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

Modern therapies such as stem cell transplant and immune therapy have made high-risk neuroblastoma a survivable disease for some children, but little is known about the chronic health issues experienced by survivors. In order to ensure that future treatments address both the chance and the quality of cure, this consortium aims to examine the impact of neuroblastoma therapy on survivors' growth, pubertal development and long-term health.

This grant is named for and funded by the "Just Do It...…and be done with it" Hero Fund created in honor of Sara Martorano who doesn't let anything dim her sparkle and has a compassionate heart and smile. It also celebrates the courage of all cancer kids through treatment and the support of their family and friends.

Cancer cells compete with the body for food. Some cancer cells use fat to grow, spread, and hide in the brain. When cancer cells hide in the brain, it is hard for chemotherapy reach them due to the blood brain barrier, which allows cancers to come back when they come out of hiding. Dr. Wang and colleagues are investigating how childhood leukemia uses fat to survive in the brain and how drugs that starve leukemia of fat can kill leukemia cells hiding in the brain.

The second year of this grant is generously supported by Rhys’ Pieces of the Cure, a Hero Fund created to honor Rhys Goldman and his journey with cancer. He was diagnosed with pre-B acute lymphoblastic leukemia just 2 weeks before his 6th birthday and endured treatment for three years. Rhys missed a lot of school and life during those years but since marking the end of treatment in July 2018, he has been enjoying swimming, singing in a boys’ choir, chess tournaments, playing with his dogs and going to school. Rhys’ Pieces for the Cure was created to ensure more research is funded for the treatment of pediatric cancer that is specifically focused on less toxic cures for kids.